New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.

ABSTRACT:

Purpose of review

Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a promising drug class for the treatment of diabetic kidney disease. Developed originally as glucose-lowering drugs by enhancing urinary glucose excretion, these drugs also lower many other renal and cardiovascular risk factors such as body weight, blood pressure, albuminuria, and uric acid. Results from the EMPA-REG OUTCOME and CANVAS trials show that these salutary effects translate into a reduction in cardiovascular outcomes and have the potential to delay the progression of kidney function decline. This review summarizes recent studies on the mechanisms and rationale of renoprotective effects.

Recent findings

Effects of SGLT-2 inhibitors on the kidney are likely explained by multiple pa

SUBMITTER: Dekkers CCJ 

PROVIDER: S-EPMC5871636 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature